Author： Shipley Lisa
Publisher： Future Science
ISSN： 1757-6199
Source： Bioanalysis, Vol.5, Iss.15, 2013-08, pp. : 1819-1820
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Lisa Shipley is Vice President of Pharmacokinetics, Pharmacodynamics and Drug Metabolism at Merck Research Laboratories. She is responsible for preclinical and clinical ADME activities and molecular biomarker assay development activities at all Merck research sites and support of all programs from discovery through to post-product launch. Prior to joining Merck in 2008, Shipley spent over 20 years at Eli Lilly and Company in roles of increasing responsibility, including the positions of executive director at Lean Six Sigma and vice president of Drug Disposition, PK/PD and Trial Simulations. Shipley obtained her undergraduate degree from McDaniel College and her doctoral degree in Pharmacology and Toxicology from the University of Maryland at Baltimore. This interview was conducted by Lisa Parks, Assistant Commissioning Editor of Bioanalysis.
Related content
Interview: Interview with James Bradner
Future Medicinal Chemistry, Vol. 5, Iss. 12, 2013-08 ,pp. :
Access to resources
Recommend
Interview: Interview with Frank Ivy Carroll
Future Medicinal Chemistry, Vol. 5, Iss. 10, 2013-06 ,pp. :
Interview: Interview with P Jeffrey Conn
Future Medicinal Chemistry, Vol. 5, Iss. 13, 2013-09 ,pp. :
Interview with Irving W Wainer
Bioanalysis, Vol. 5, Iss. 16, 2013-08 ,pp. :
Interview with Line Matthiessen
Future Medicinal Chemistry, Vol. 5, Iss. 11, 2013-07 ,pp. :